Janssen’s Zytiga approved for earlier use in prostate cancer
European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer.
Read More
Tag: mHSPC
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
